Cell Therapeutics Settles Investor Lawsuit For $19M
Seattle-based biotechnology company Cell Therapeutics Inc. agreed to pay $19 million to settle a class action by investors who contended the company's stock price was artificially inflated due to misleading statements...To view the full article, register now.
Already a subscriber? Click here to view full article